Advancements in the Management of R/R AML: ASH 2024 - Episode 12

Closing Perspectives on R/R AML Treatment Advances

, , , , ,

Panelists discuss future perspectives on the role of menin inhibitors in the treatment of acute lymphoblastic leukemia (AML), exploring potential advancements and clinical implications.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Treatment Strategies for Relapsed/Refractory AML Patients
    EP. 2: Treatment Goals and Unmet Needs in R/R AML
    EP. 3: Navigating Challenges in Second- and Third-Line AML Therapy
    EP. 4: Revumenib’s FDA Approval and Clinical Implications
    EP. 5: Efficacy and Potential of Revumenib in KMT2A-Translocated Leukemia
    EP. 6: Adverse Event Management and Patient Safety With Revumenib
    EP. 7: MRD Testing and the Role of Revumenib in Treatment Response
    EP. 8: Integrating Revumenib Into Current R/R AML Treatment Paradigms
    EP. 9: Genetic Testing and Molecular Profiling in AML
    EP. 10: Emerging Combination Strategies and Preclinical Findings
    EP. 11: Future Perspectives on Menin Inhibitors in Acute Leukemias
    Now Viewing
    EP. 12: Closing Perspectives on R/R AML Treatment Advances

    Video content above is prompted by the following:

    Dr. LeBlanc to ask GROUP: Please share future perspectives on the role of menin inhibitors in AML treatment.

    x